Akari Therapeutics, Plc AKTX announced that the FDA has granted an orphan drug designation to its lead pipeline candidate nomacopan for the treatment of bullous pemphigoid (“BP”). Currently, there is no approved therapy for this rare disease, which causes severe blistering of the skin. The status makes nomacopan eligible for seven years of marketing exclusivity in the United States.
Notably, the orphan drug designation is granted to drugs capable of treating rare diseases that affect less than 200,000 people in the United States. This designation also makes the company entitled to certain other benefits including tax credits related to clinical study expenses and an exemption from certain administrative fees.
The company is currently evaluating the candidate in a phase II study for treating patients with BP. In April, it had reported positive initial data from this study.
Please note that nomacopan was granted orphan drug designation for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) by the FDA last month.
Shares of Akari have increased 21.6% so far this year against the industry’s decline of 1.7%.
Nomacopan is a C5 complement inhibitor that specifically inhibits leukotriene B4 (LTB4) activity. Complement component C5, the target of nomacopan, is mostly found in the blood. Pre-clinical studies on nomacopan demonstrated that it is significantly more effective than LTB4 or C5 alone. Currently marketed LTB4 and C5 drugs include Zileuton and Alexion Pharmaceuticals’ ALXN Soliris, respectively.
Apart from BP, the company is developing the candidate in three other rare diseases — HSCT-TMA, atopic keratoconjunctivitis ("AKC") and paroxysmal nocturnal hemoglobinuria ("PNH").
Nomacopan is in most advanced stage of development as a treatment for HSCT-TMA in pediatric patients. The company is planning to initiate a pivotal phase III study for this indication in the fourth quarter of 2019. Meanwhile, the company has successfully completed a phase II study, evaluating the candidate in PNH patients.
With no approved products, the company is dependent on successful development of nomacopan.
Akari Therapeutics PLC Price
Akari Therapeutics PLC price | Akari Therapeutics PLC Quote
Zacks Rank & Stocks to Consider
Akari currently carries a Zacks Rank #5 (Strong Sell).
A couple of better-ranked stocks in the healthcare sector include Emmaus Life Sciences EMMA and Acorda Therapeutics ACOR, both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emmaus Life’s loss per share estimates have narrowed 17.8% for 2019 and 26.4% for 2020 over the past 60 days.
Acorda’s loss per share estimates have narrowed 27.7% for 2019 and 4.6% for 2020 over the past 60 days.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Acorda Therapeutics, Inc. (ACOR) : Free Stock Analysis Report
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
Emmaus Life Sciences, Inc. (EMMA) : Free Stock Analysis Report
Akari Therapeutics PLC (AKTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.